IMNM,BMRN Stock Price and Quote

Peers: ZYME CTMX STRO IDYA PYXS TNGX AKTS BCYC ADCT CATX

| Held by: VTI IWM XBI VXF IWO VTWO SCHA VHT CANC ITOT

Index	RUT
Market Cap	2.15B
Enterprise Value	1.63B
Income	-254.32M
Sales	0.00M
Book/sh	4.63
Cash/sh	4.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	177
IPO	Oct 02, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.93
P/C	4.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.08
Current Ratio	15.08
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.53
EPS next Y	-2.49
EPS next Q	-0.60
EPS this Y	3.59%
EPS next Y	-6.17%
EPS next 5Y	12.49%
EPS past 3/5Y	7.72% -7.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	18.12%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-29.43%
Sales Q/Q	-100.00%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-26.51% -100.00%

Insider Own	8.30%
Insider Trans	-6.59%
Inst Own	99.59%
Inst Trans	-0.60%
ROA	-59.03%
ROE	-64.03%
ROIC	-48.02%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-0.79%
SMA50	-18.85%
SMA200	-19.04%
Trades

Shs Outstand	113.40M
Shs Float	108.21M
Short Float	15.97%
Short Ratio	13.58
Short Interest	17.28M
52W High	30.06 -39.42%
52W Low	14.64 24.39%
Volatility	5.79% 5.40%
ATR (14)	1.01
RSI (14)	39.46
Beta	2.67
Rel Volume	1.00
Avg Volume	1.27M
Volume	1,271,034

Perf Week	1.22%
Perf Month	-12.83%
Perf Quarter	-20.86%
Perf Half Y	-19.89%
Perf YTD	-15.22%
Perf Year	13.95%
Perf 3Y	106.93%
Perf 5Y	-22.31%
Perf 10Y	-
Recom	1.18
Target Price	35.33
Prev Close	18.29
Price	18.21
Change %	-0.44%

Consensus

Strong Buy

Avg. Price Target

$35.33

Implied Upside

+94.0%

Analysts16incl. previous ratings

Rating Distribution15 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2026	Initiated	WWilliam Blair	Outperform
Oct 01, 2026	Initiated	SStifel	Hold	$24	+31.8%
Sep 21, 2026	Initiated	AAlliance Global Partners	Buy	$32	+75.7%
May 28, 2026	Initiated	BBarclays	Overweight	$36	+97.7%
Feb 12, 2026	Initiated	HH.C. Wainwright	Buy	$40	+119.7%
Dec 01, 2025	Initiated	TTruist	Buy	$36	+97.7%
Sep 22, 2025	Initiated	GGoldman	Buy	$26	+42.8%
Sep 05, 2025	Initiated	CCraig Hallum	Buy	$26	+42.8%
Apr 02, 2025	Initiated	LLake Street	Buy	$23	+26.3%
Nov 08, 2024	Initiated	SStephens	Overweight	$30	+64.7%
May 31, 2024	Initiated	PPiper Sandler	Overweight	$27	+48.3%
Apr 30, 2024	Initiated	JJP Morgan	Overweight	$24	+31.8%
Apr 15, 2024	Initiated	GGuggenheim	Buy	$35	+92.2%
Jan 29, 2024	Initiated	LLeerink Partners	Outperform	$30	+64.7%
Dec 19, 2023	Initiated	WWedbush	Outperform	$12	-34.1%
Oct 29, 2021	Initiated	CCantor Fitzgerald	Overweight	$35	+92.2%

Oct-30-26 07:30AM	Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Oct-26-26 07:00AM	Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 (Business Wire)
Oct-06-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.79%
Sep-30-26 07:45AM	Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors (Business Wire)
Sep-08-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Loading…
Sep-02-26 07:45AM	Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
Aug-11-26 04:02PM	Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire) +6.63%
Aug-06-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-20-26 07:30AM	Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors (Business Wire)
Jul-08-26 07:30AM	Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Jul-07-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-26 07:30AM	Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors (Business Wire)
Jun-04-26 04:02PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.59%
May-30-26 08:00AM	Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting (Business Wire)
May-28-26 11:26AM	Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
08:00AM	Loading…
May-27-26 08:00AM	Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire)
May-12-26 04:02PM	Immunome Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-26 07:30AM	Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors (Business Wire)
Apr-21-26 10:30AM	Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting (Business Wire)
Apr-02-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.97%
Mar-03-26 04:02PM	Immunome Reports Full Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-02-26 02:57AM	Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development (Insider Monkey)
Feb-23-26 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 11:03PM	Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses (MarketBeat)
Feb-12-26 09:44AM	Shopify upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More (24/7 Wall St.)
Feb-05-26 04:00PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.13%
Feb-04-26 08:00AM	Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (Business Wire)
11:35AM	Loading…
Jan-15-26 11:35AM	Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? (Insider Monkey) +10.07%
Jan-08-26 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:45AM	Jim Cramer on Immunome: "If You Want to Speculate on It, Fine" (Insider Monkey)
Jan-06-26 08:00AM	Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 08:05PM	Lightning Round: Nokia is up against a lot of tough companies, says Jim Cramer (CNBC TV) -5.33%
Dec-16-25 08:16PM	Immunome Announces Pricing of Public Offering of Common Stock (Business Wire) -15.76%
07:26AM	Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win (Clinical Trials Arena)
Dec-15-25 06:03PM	Why Immunome Stock Surged Today (Motley Fool) +15.69%
04:36PM	Stocks Fall Ahead of US November Payroll Report (Barchart)
04:34PM	Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA (Investor's Business Daily)
04:01PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
12:53PM	Stock Market Today: Russell 2000, Nasdaq Decline After Strong Start to Trading Week (TheStreet)
07:00AM	Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-14-25 04:00PM	Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors (Business Wire)
Dec-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-25-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire)
Nov-06-25 04:05PM	Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-04-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.35%
Oct-31-25 11:51AM	Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference (Business Wire)
Oct-23-25 12:00PM	Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance (Business Wire)
Oct-02-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.93%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) -9.33%
Sep-18-25 08:00AM	Infinimmune Announces Research Collaboration with Immunome (Business Wire) +9.57%
Sep-04-25 05:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.35%
Sep-03-25 08:00AM	Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire) +10.45%
Aug-22-25 09:35AM	Gap downgraded, Ulta upgraded: Wall Street's top analyst calls (The Fly)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.64%
05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire)
Aug-05-25 05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 05:51PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-25 10:29AM	Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks) -8.98%
Jun-16-25 12:00PM	Immunome (IMNM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-12-25 09:55AM	Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? (Zacks)
Jun-05-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-25 09:55AM	Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet (Zacks)
May-22-25 08:00AM	Immunome to Present at Upcoming Investor Conferences (Business Wire) +6.82%
May-13-25 12:00PM	All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.43%
05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Immunome Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-08-25 09:55AM	Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade (Zacks)
May-02-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 06:06AM	Immunome: Transformed Pipeline Offers Multiple Catalysts (Seeking Alpha) +10.32%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Apr-04-25 08:00AM	Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Apr-03-25 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
Mar-26-25 08:00PM	Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement (TipRanks)
Mar-19-25 05:35PM	Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immunome Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-10-25 07:41AM	Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC (Business Wire) -5.25%
Mar-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-25-25 08:00AM	Immunome to Present at Upcoming March Conferences (Business Wire)
Feb-06-25 04:01PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-31-25 04:01PM	Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (Business Wire) -6.44%
Jan-29-25 11:11PM	Immunome Announces Pricing of Upsized Public Offering of Common Stock (Business Wire) +12.41%
04:27PM	Immunome Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-13-25 08:00AM	Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -5.28%
Jan-07-25 08:00AM	Hummingbird Bioscience Licenses Novel Antibodies to Immunome (GlobeNewswire)
Jan-02-25 06:03PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.03%
Dec-02-24 06:26PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-24 01:22PM	Hedge Fund and Insider Trading News: Scott Bessent, Paloma Partners, Taula Capital Management, Immunome Inc (IMNM), AppLovin Corp (APP), and More (Insider Monkey) +16.83%
08:00AM	Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-13-24 05:15PM	Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -7.21%
04:05PM	Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-05-24 08:00AM	Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference (Business Wire)
Nov-01-24 04:05PM	Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.53%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higgins Jack	Chief Scientific Officer	Sep 11 '26	Option Exercise	1.35	18,000	24,300	78,250	Sep 15 04:30 PM
Higgins Jack	Chief Scientific Officer	Sep 11 '26	Sale	25.32	13,200	334,224	65,050	Sep 15 04:30 PM
Higgins Jack	Officer	Sep 11 '26	Proposed Sale	25.32	13,200	334,224		Sep 11 10:20 AM
Barchas Isaac	Director	Aug 11 '26	Sale	26.23	62,291	1,633,893	0	Aug 12 05:47 PM
Barchas Isaac	Director	Aug 12 '26	Sale	27.25	11,048	301,058	92,211	Aug 12 05:47 PM
Barchas Isaac	Director	Aug 10 '26	Sale	26.07	10,125	263,959	62,291	Aug 12 05:47 PM
Barchas Isaac	Director	Aug 12 '26	Proposed Sale	27.25	11,048	301,058		Aug 12 11:40 AM
Barchas Isaac	Director	Aug 06 '26	Sale	26.06	20,840	543,090	87,664	Aug 10 04:10 PM
Barchas Isaac	Director	Aug 07 '26	Sale	26.06	15,248	397,363	72,416	Aug 10 04:10 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Aug 04 '26	Option Exercise	11.89	90,616	1,077,379	90,616	Aug 06 06:30 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Aug 04 '26	Sale	25.09	90,616	2,273,555	0	Aug 06 06:30 PM
ABHMC II, LLC	Shareholder	Aug 06 '26	Proposed Sale	25.52	108,504	2,769,022		Aug 06 05:41 PM
Horn Kinney	Officer	Aug 04 '26	Proposed Sale	25.09	90,616	2,274,007		Aug 04 04:32 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 07 '26	Option Exercise	12.92	1,092	14,109	1,092	Jul 09 05:38 PM
Horn Kinney	CHIEF BUSINESS OFFICER	Jul 07 '26	Sale	25.00	1,092	27,300	0	Jul 09 05:38 PM
Barchas Isaac	Director	Jul 06 '26	Sale	24.11	83,094	2,003,396	125,410	Jul 07 07:02 PM
Barchas Isaac	Director	Jul 07 '26	Sale	24.20	16,906	409,125	108,504	Jul 07 07:02 PM
Lechleider Robert	Chief Medical Officer	Jul 02 '26	Option Exercise	8.73	55,000	480,150	70,805	Jul 07 05:42 PM
Lechleider Robert	Chief Medical Officer	Jul 02 '26	Sale	22.62	55,000	1,244,331	15,805	Jul 07 05:42 PM
Horn Kinney	Officer	Jul 07 '26	Proposed Sale	25.00	1,092	27,300		Jul 07 04:04 PM
ABHMC II, LLC	Shareholder	Jul 06 '26	Proposed Sale	23.61	100,000	2,361,000		Jul 06 05:37 PM
Barchas Isaac	Director	Jul 02 '26	Sale	22.59	100,000	2,258,848	208,504	Jul 02 08:31 PM
Barchas Isaac	Director	Jun 30 '26	Sale	21.12	101,050	2,134,176	308,504	Jul 02 08:31 PM
ABHMC II, LLC	Shareholder	Jul 02 '26	Proposed Sale	21.49	100,000	2,149,000		Jul 02 04:42 PM
Lechleider Robert	Officer	Jul 02 '26	Proposed Sale	21.60	55,000	1,188,000		Jul 02 12:07 PM
ABHMC II, LLC	Shareholder	Jun 30 '26	Proposed Sale	21.04	100,000	2,104,000		Jun 30 05:20 PM
Arsenal Bridge Venture II-B, L	Shareholder	Jun 30 '26	Proposed Sale	21.04	1,050	22,092		Jun 30 05:20 PM
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Option Exercise	8.73	55,000	480,150	70,805	Jun 29 04:52 PM
Lechleider Robert	Chief Medical Officer	Jun 25 '26	Sale	19.85	55,000	1,091,662	15,805	Jun 29 04:52 PM
Lechleider Robert	Officer	Jun 25 '26	Proposed Sale	19.73	55,000	1,085,150		Jun 25 09:47 AM
Rosett Max	Chief Financial Officer	Jun 15 '26	Option Exercise	1.05	60,000	63,000	114,037	Jun 17 05:26 PM
Rosett Max	Chief Financial Officer	Jun 15 '26	Sale	18.23	60,000	1,093,800	54,037	Jun 17 05:26 PM
Rosett Max	Officer	Jun 15 '26	Proposed Sale	18.63	60,000	1,117,800		Jun 15 02:36 PM
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Buy	19.45	10,500	204,260	43,415	Jun 09 05:40 PM
BIENAIME JEAN JACQUES	Director	Jun 05 '26	Sale	19.41	10,500	203,820	32,915	Jun 09 05:40 PM
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	20.70	5,000	103,500	43,415	May 19 07:56 AM
Higgins Jack	Chief Scientific Officer	Apr 02 '26	Sale	21.64	9,438	204,238	22,000	Apr 03 07:48 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Option Exercise	1.22	71,561	87,053	119,037	Apr 03 07:46 PM
Rosett Max	Chief Financial Officer	Apr 02 '26	Sale	21.92	65,000	1,424,916	54,037	Apr 03 07:46 PM
Rosett Max	Officer	Apr 02 '26	Proposed Sale	72.67	65,000	4,723,550		Apr 02 11:46 AM
Higgins Jack	Officer	Apr 02 '26	Proposed Sale	21.64	9,438	204,238		Apr 02 11:32 AM
SIEGALL CLAY B	President and CEO	Mar 27 '26	Buy	19.67	25,450	500,602	690,704	Mar 31 07:11 AM
WAGENHEIM PHILIP	Director	Mar 20 '26	Sale	20.47	36,800	753,296	369,347	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 23 '26	Sale	20.65	28,200	582,330	341,147	Mar 23 09:23 PM
WAGENHEIM PHILIP	Director	Mar 20 '26	Proposed Sale	20.81	65,000	1,352,640		Mar 20 12:56 PM
BIENAIME JEAN JACQUES	Director	Mar 10 '26	Buy	22.12	1,000	22,120	37,415	Mar 12 06:05 AM
BIENAIME JEAN JACQUES	Director	Mar 11 '26	Buy	21.55	1,000	21,550	38,415	Mar 12 06:05 AM
SIEGALL CLAY B	President and CEO	Dec 30 '25	Buy	21.15	4,729	100,018	665,254	Dec 30 06:47 PM
Barchas Isaac	Director	Dec 22 '25	Sale	21.74	383,200	8,330,080	2,031,181	Dec 23 04:41 PM
SIEGALL CLAY B	President and CEO	Dec 19 '25	Buy	20.48	7,278	149,053	860,525	Dec 22 07:38 AM
Tsai Philip	Chief Technical Officer	Dec 19 '25	Buy	20.49	10,000	204,900	43,300	Dec 22 07:32 AM
SIEGALL CLAY B	President and CEO	Dec 18 '25	Buy	21.50	46,511	999,986	853,247	Dec 18 05:03 PM

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. It also focuses on oncology and infectious disease areas. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Bothell, WA.

ChairmanDr. Clay B. Siegall Ph.D.

Chief Financial OfficerMr. Max Rosett

Chief Medical OfficerDr. Robert J. Lechleider M.D.

Chief Technical OfficerDr. Philip Tsai

Chief Scientific OfficerDr. Jack Higgins Ph.D.

IMNM

Immunome Inc

BMRN

Biomarin Pharmaceutical Inc

Upgrade your Finviz experience